Partner Therapeutics said its bispecific antibody Bizengri received FDA approval for advanced cases of cholangiocarcinoma driven by NRG1 gene fusions. The therapy was acquired as U.S. rights from Merus in 2024, bringing a targeted option to a rare, genomically defined cancer subtype. The approval marks the first FDA-authorized therapy for this molecular driver in the reported indication, reinforcing the continued clinical focus on narrow biomarker-defined oncology populations. It also highlights how licensing deals can accelerate access to targeted agents once clinical evidence is complete. The report did not include label specifics, confirmatory-study status, or commercial timeline details.